Imugene Ltd has released a press release.
Imugene doses first patient in nextHERIZON Phase 2 trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Imugene
- Imugene Dose Escalates in Phase I Clinical Trial of VAXINIA
- Annual Report and Appendix 4E
- First cohort 3 patient dosed in clinical trial of checkvacc
- Imugene Presents New PD1-Vaxx Data at the 2022 WCLC
- Final HER-Vaxx Phase 2 Trial Overall Survival Results
Later from Imugene
- Imugene announces a$80 million institutional placement
- Prospectus for the issue of institutional placement options
- OGTR grants VAXINIA DIR licence allowing trial expansion
- First patient IV dosed in VAXINIA Phase 1 clinical trial
- Preclinical trial of ALA iNKT therapy and IMU onCARlytics
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene